Incyte (INCY) Named 2019 Best Idea at Cowen

Cowen analyst Marc Frahm named Incyte (NASDAQ: INCY) a Best Idea for 2019. The firm reiterated an Outperform rating.

Frahm commented, "We expect Incyte's base business to continue to provide strong support to shares in the low $60s. Multiple pipeline programs are set to achieve important milestones over the next ~12-16 months with minimal expectations priced in. As investors gain a greater appreciation for the sales potential of these assets, we expect shares to be among the best performing mid/large caps in the biotech sector."

For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.

Shares of Incyte closed at $65.10 yesterday.

You May Also Be Interested In

• Invesco (IVZ) PT Raised to $39 at TD Cowen
• JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
• Riskified Ltd. (RSKD) PT Raised to $7.50 at DA Davidson on Improving New Business Trends